Rexahn Pharmaceuticals Inc. (RNN)

1.75
0.10 5.40
AMEX : Health Technology
Prev Close 1.85
Open 1.80
Day Low/High 1.74 / 1.83
52 Wk Low/High 1.42 / 3.19
Volume 298.14K
Avg Volume 322.90K
Exchange AMEX
Shares Outstanding 31.74M
Market Cap 59.52M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Rexahn Pharmaceuticals Provides Key Goals For 2013

Rexahn Pharmaceuticals Provides Key Goals For 2013

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company focused on developing first in class therapies for the treatment of cancer, today provided an update on its strategic business...

Rexahn Pharmaceuticals Appoints Peter D. Suzdak As Chief Executive Officer

Rexahn Pharmaceuticals Appoints Peter D. Suzdak As Chief Executive Officer

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage pharmaceutical company developing potential first in class oncology and CNS therapeutics, today announced that it has appointed Dr.

Rexahn Pharmaceuticals Expands Its Intellectual Property Around Class Of Potent Anti-cancer Isoquinolinamine Compounds

Rexahn Pharmaceuticals Expands Its Intellectual Property Around Class Of Potent Anti-cancer Isoquinolinamine Compounds

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has significantly expanded its...

Rexahn Pharmaceuticals Closes Public Offering For $6,600,000 In Gross Proceeds

Rexahn Pharmaceuticals Closes Public Offering For $6,600,000 In Gross Proceeds

REXAHN PHARMACEUTICALS, INC. (NYSE MKT: RNN) announced today the closing of its previously announced underwritten public offering of 19,130,435 units and a partial exercise of the over-allotment option by the ...

Rexahn Pharmaceuticals Prices Public Offering Of Stock

Rexahn Pharmaceuticals Prices Public Offering Of Stock

REXAHN PHARMACEUTICALS, INC. (NYSE MKT: RNN) today announced the pricing of an underwritten public offering of 19,130,435 shares of its common stock and warrants exercisable for up to 10,521,739 additional shares at $0.

Rexahn Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrant

Rexahn Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrant

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) today announced that it intends to offer shares of its common stock and warrants to purchase common stock in an underwritten public offering.

Teva Pharmaceutical To Increase Ownership In Rexahn

Teva Pharmaceutical To Increase Ownership In Rexahn

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best-in-class oncology and central nervous system (CNS) therapeutics, today announced that Teva ...

Rexahn Pharmaceuticals Issued US Patent For Quinoxalinyl-piperazine Compounds

Rexahn Pharmaceuticals Issued US Patent For Quinoxalinyl-piperazine Compounds

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United...

Rexahn Pharmaceuticals Granted European Patent For Novel Anti-cancer Isoquinolinamine Compounds

Rexahn Pharmaceuticals Granted European Patent For Novel Anti-cancer Isoquinolinamine Compounds

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted...

Rexahn Pharmaceuticals To Present At The Rodman & Renshaw 14th Annual Healthcare Conference

Rexahn Pharmaceuticals To Present At The Rodman & Renshaw 14th Annual Healthcare Conference

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced that it will present at the Rodman...

Rexahn Pharmaceuticals Provides Update On 2012 Strategic Goals

Rexahn Pharmaceuticals Provides Update On 2012 Strategic Goals

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today provided an update on its strategic business...

Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta

Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Rexahn Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference

Rexahn Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced that it will present at the Stifel...

Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data For Archexin In Patients With Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data For Archexin In Patients With Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II...

Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117

Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase...

Rexahn Submits An Investigational New Drug Application To The FDA For First-in-Class P68 Helicase Inhibitor, RX-5902

Rexahn Submits An Investigational New Drug Application To The FDA For First-in-Class P68 Helicase Inhibitor, RX-5902

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an...

Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117

Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research...

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase...

Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting

Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data...

Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117

Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled the first subject in...

Rexahn Pharmaceuticals Publishes New Preclinical Data For Quinoxalinyl-Piperazine Compounds

Rexahn Pharmaceuticals Publishes New Preclinical Data For Quinoxalinyl-Piperazine Compounds

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing best in class oncology and CNS therapeutics, today announced the publication of preclinical results...

Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors

Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority...

Rexahn Pharmaceuticals Provides Key Goals For 2012

Rexahn Pharmaceuticals Provides Key Goals For 2012

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2012.

Rexahn Pharmaceuticals Announces Phase II Results For Serdaxin® As Treatment For Major Depressive Disorder

Rexahn Pharmaceuticals Announces Phase II Results For Serdaxin® As Treatment For Major Depressive Disorder

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of...

Rexahn Pharmaceuticals Granted US Patent For Novel Anti-cancer Isoquinolinamine Compounds

Rexahn Pharmaceuticals Granted US Patent For Novel Anti-cancer Isoquinolinamine Compounds

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & ...

Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin®

Rexahn Pharmaceuticals Announces Publication Of Study Validating Mechanism Of Action Of Serdaxin®

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a peer...

Rexahn Pharmaceuticals Completes Patient Enrollment For Archexin Phase II Clinical Trial In Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals Completes Patient Enrollment For Archexin Phase II Clinical Trial In Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its...

Rexahn Pharmaceuticals To Present At The Rodman & Renshaw 13th Annual Healthcare Conference

Rexahn Pharmaceuticals To Present At The Rodman & Renshaw 13th Annual Healthcare Conference

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it will present at the...

Rexahn Pharmaceuticals Announces US Patent Issued For CNS-based Treatment Of Sexual Dysfunction

Rexahn Pharmaceuticals Announces US Patent Issued For CNS-based Treatment Of Sexual Dysfunction

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent and Trademark...

European Patent Granted For Neurotherapeutic Compositions

European Patent Granted For Neurotherapeutic Compositions

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has...